Skip to main content
Depletion Comparison · Based on CTD Molecular Database

Metoprolol vs Atenolol: Nutrient Depletion Comparison

Metoprolol (Lopressor) and atenolol (Tenormin) both deplete CoQ10 and melatonin through beta-1 receptor blockade. Metoprolol's lipophilic nature lets it cross the blood-brain barrier and more aggressively suppress pineal melatonin, while atenolol's hydrophilic structure limits CNS penetration — potentially preserving sleep architecture better despite depleting the same two nutrients.

Compare YOUR medications' depletionsFree, 10 seconds →

Data sourced from CTD, ChEMBL, FAERS, PharmGKB. How we verify this data →
Sources verified as of April 2026
[01]

At a Glance

Drug A
Metoprolol
2 depletions

Metoprolol selectively blocks beta-1 adrenergic receptors, reducing heart rate and cardiac output. Beta-1 blockade suppresses the sympathetic nervous system's stimulation of pineal melatonin synthesis — the pineal gland relies on beta-1 receptor activation to produce melatonin at night. Metoprolol's lipophilic structure allows it to cross the blood-brain barrier freely, reaching the pineal gland at high concentrations and creating more aggressive melatonin suppression than hydrophilic beta-blockers. CTD documents gene interactions affecting both adrenergic signaling and mitochondrial CoQ10-dependent electron transport.

Metoprolol has 38% oral bioavailability due to extensive first-pass CYP2D6 metabolism, with a short 3.6-hour half-life requiring twice-daily dosing (or extended-release for once-daily). CYP2D6 poor metabolizers experience dramatically higher drug levels.

Pros
  • Proven mortality reduction in heart failure (MERIT-HF trial, 3,991 patients)
  • Extended-release formulation (succinate) allows once-daily dosing despite short half-life
  • Lipophilic properties provide better anxiolytic effects through CNS penetration
  • PharmGKB Level 1A evidence for CYP2D6 pharmacogenomic dosing guidance
Cons
  • Lipophilic CNS penetration causes more vivid dreams, nightmares, and sleep disruption from melatonin suppression
  • CYP2D6-dependent metabolism creates significant drug interaction risks and genetic variability in blood levels
  • 38% bioavailability means most of the drug is lost to first-pass metabolism — unpredictable in CYP2D6 poor metabolizers
  • Short 3.6-hour half-life (IR form) requires strict twice-daily timing
Best For

Heart failure patients (per MERIT-HF evidence), those with performance anxiety benefiting from CNS effects, and patients who can use CYP2D6 pharmacogenomic testing to guide dosing.

Drug B
Atenolol
2 depletions

Atenolol blocks the same beta-1 receptors but its hydrophilic (water-soluble) structure limits blood-brain barrier penetration. This means atenolol suppresses melatonin less aggressively than metoprolol because it reaches the pineal gland at lower concentrations. However, peripheral beta-1 blockade still reduces the sympathetic drive to melatonin synthesis, so some melatonin suppression occurs. CoQ10 depletion happens through the same mechanism as metoprolol — reduced mitochondrial energy production through beta-adrenergic pathway modulation.

Atenolol achieves 58% oral bioavailability without CYP metabolism — it's renally eliminated unchanged, meaning no CYP2D6 drug interactions and consistent blood levels regardless of genetic polymorphisms. Half-life is 6.1 hours allowing once-daily dosing.

Pros
  • Hydrophilic structure causes fewer CNS side effects — less insomnia, fewer nightmares, less vivid dreaming
  • No CYP450 metabolism — eliminated renally unchanged, eliminating drug interaction complexity
  • Higher bioavailability (58% vs 38%) provides more consistent blood levels without genetic variability
  • Once-daily dosing with 6.1-hour half-life simplifies adherence
Cons
  • Less proven heart failure mortality benefit compared to metoprolol succinate's MERIT-HF evidence
  • ASCOT-BPLA trial raised concerns about atenolol-based regimens for cardiovascular outcomes vs newer agents
  • Renal elimination means dose adjustment required in kidney disease — impaired patients accumulate the drug
  • Still depletes melatonin peripherally even without strong CNS penetration — sleep disruption still possible
Best For

Patients who experience insomnia or nightmares on lipophilic beta-blockers, those with multiple CYP2D6-metabolized medications, or patients who need a beta-blocker without CNS side effects.

[02]

Feature Comparison

FeatureMetoprololAtenolol
Drug ClassBeta-1 selective blocker (lipophilic)Beta-1 selective blocker (hydrophilic)
Nutrients Depleted2 — CoQ10, melatonin2 — CoQ10, melatonin
Bioavailability38% (CYP2D6-dependent)58% (renal, no CYP)
Half-Life3.6 hours (IR) / 12h (XR)6.1 hours
CNS PenetrationHigh (lipophilic — crosses BBB)Low (hydrophilic — limited BBB crossing)
Melatonin SuppressionMore aggressive (CNS + peripheral)Less aggressive (primarily peripheral)
MetabolismCYP2D6 hepatic (genetic variability)Renal elimination (no CYP)
HF Mortality EvidenceMERIT-HF (3,991 patients)Limited direct evidence

Wondering which medication depletes less?

Check your medications free — 10 seconds →
[03]

Verdict

Both beta-blockers deplete the same two nutrients — CoQ10 and melatonin — through beta-1 receptor blockade, and both benefit from the same supplementation protocol. The critical differentiator is CNS access. Metoprolol's lipophilic structure crosses the blood-brain barrier freely, creating more aggressive pineal melatonin suppression that causes insomnia, vivid dreams, and nightmares — the most common reason patients abandon beta-blocker therapy. Atenolol's hydrophilic structure limits CNS penetration, causing less melatonin disruption and fewer sleep-related side effects. For heart failure, metoprolol succinate has MERIT-HF mortality data that atenolol lacks. For hypertension with sleep concerns, atenolol's CNS-sparing profile and CYP-free metabolism make it the gentler choice. Either way, CoQ10 100 mg ubiquinol and melatonin 0.3–0.5 mg at bedtime address the complete two-nutrient depletion burden.

[04]

FAQ

[05]

References

  1. [1]MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure. Lancet. 1999;353(9169):2001-2007
  2. [2]CTD (Comparative Toxicogenomics Database): gene interactions for both drugs affecting beta-adrenergic and melatonin synthesis pathways
  3. [3]FAERS (FDA Adverse Event Reporting System): safety reports for both metoprolol and atenolol across cardiovascular indications
  4. [4]PharmGKB pharmacogenomics database: CYP2D6 Level 1A evidence for metoprolol dosing; renal elimination annotations for atenolol
  5. [5]PubMed PMID 10789600 — Stoschitzky K et al. Influence of beta-blockers on melatonin release. Eur J Clin Pharmacol. 1999;55(2):111-115
This information is generated from peer-reviewed molecular databases including the Comparative Toxicogenomics Database (CTD), ChEMBL, and indexed PubMed research. It is not medical advice. Always consult your healthcare provider before making changes to your medications or supplements. See our methodology →

Compare All Your Medications

Free. No signup. 10 seconds.

Check Now →